<h1 id="ectopic-pregnancy-and-methotrexate">Ectopic Pregnancy and Methotrexate</h1>
<ul>
<li>2% of all first-trimester pregnancies and 6% of all pregnancy-related deaths</li>
<li>18% of patients who present with first-trimester bleeding or abdominal pain in the Emergency Department</li>
<li><p>Risk factors</p>
<ul>
<li>Prior tubal, pelvic, or abdominal surgery</li>
<li>Genital infections leading to pelvic inflammatory disease</li>
<li>Prior ectopic pregnancy</li>
<li>In utero exposure to diethylstilbestrol (DES)</li>
<li>History of infertility</li>
<li>Use of assisted reproductive technologies (in vitro fertilization)</li>
<li>Tobacco use</li>
</ul>
</li>
</ul>
<h2 id="methotrexate-mtx-">Methotrexate (MTX)</h2>
<p><strong>Background</strong></p>
<ul>
<li>Dihydrofolate reductase inhibitor</li>
<li>Overall success rate for treating ectopic pregnancy = 71-94%</li>
<li>Success rate of single-dose MTX for B-hCG &gt; 5,000 mIU/mL = 85.7% </li>
</ul>
<p><strong>Side Effects</strong></p>
<ul>
<li>Abdominal pain</li>
<li>Nausea/vomiting</li>
<li>Stomatitis    </li>
</ul>
<h2 id="eligibility-contraindications-for-mtx-in-ectopic-pregnancy">Eligibility / Contraindications for MTX in Ectopic Pregnancy</h2>
<p><strong>Eligibility Criteria:</strong></p>
<ul>
<li>High clinical suspicion or confirmed ectopic pregnancy,</li>
<li>Hemodynamically stable,</li>
<li>Unruptured mass,</li>
<li>Able to comply with close follow-up, <strong>AND</strong></li>
<li>Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts </li>
</ul>
<p><strong>Contraindications:</strong></p>
<ul>
<li>Breastfeeding</li>
<li>Overt or lab evidence of immunodeficiency</li>
<li>Alcoholism, alcoholic or chronic liver disease</li>
<li>Preexisting blood dyscrasias or significant anemia </li>
<li>Known sensitivity to MTX</li>
<li>Active pulmonary disease</li>
<li>Peptic ulcer disease</li>
<li>Hepatic, renal, or hematologic dysfunction</li>
<li>Gestational sac &gt; 3.5 cm on U/S (relative contraindication) </li>
<li>Embryonic cardiac motion on U/S (relative contraindication) </li>
</ul>
<h2 id="single-dose-regimen">Single-Dose Regimen</h2>
<ul>
<li><span class="drug">Methotrexate</span> 50 mg/m2 IM on Day 1</li>
</ul>
<p><strong>Follow up with obstetrician to:</strong></p>
<ul>
<li>Measure B-hCG on Days 4 and 7</li>
<li>Check for 15% B-hCG decrease between days 4 and 7</li>
<li>Measure B-hCG weekly until non-pregnant level</li>
<li>If B-hCG dose not decrease by &gt;15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. </li>
</ul>
<h2 id="alternative-regimens">Alternative Regimens</h2>
<ul>
<li><strong>Two-Dose</strong> and <strong>Fixed Multidose</strong> regimens available as proposed by ACOG guidelines - Consider for B-hCG level &gt; 5,000 mIU/mL</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18515537">ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85.</a></li>
</ul>
